Barclays’s General Moly, Inc. GMO Stock Holding History

Barclays’s Portfolio GMO Stock Details GMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-4,300	Closed	-$8K	–	7699
2013 Q2	$8K	Buy	+4,300	New	+$8.46K	﹤0.01%	7228

Other funds holding GMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays's GMO Position: Q3 2020 in Review

Barclays sold out of General Moly, Inc. (GMO) in Q3 2020, closing a stake of 800 shares.

Barclays first reported a position in GMO in Q2 2013 and held it in 8 quarters. The position peaked at $21K in Q2 2013. 31 funds tracked by Wall St. Rank hold GMO as of Q3 2020.

Barclays reported no remaining General Moly, Inc. position as of Q3 2020 after selling out during the quarter.
Barclays sold 800 General Moly, Inc. shares in Q3 2020.
Barclays first reported a position in General Moly, Inc. in Q2 2013 and held it in 8 quarters.
Barclays's General Moly, Inc. position peaked at $21K in Q2 2013.
31 funds tracked by Wall St. Rank held General Moly, Inc. as of Q3 2020.

Based on Barclays's 13F filing for Q3 2020, filed 12 Nov 2020.